Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2007

Arius Inks Manufacturing Agreement with Avid Bioservices

  • Arius Research entered into a manufacturing supply and technology transfer agreement for its CD44 cancer stem cell antibody with Avid Bioservices. The company has already begun manufacturing a supply of the drug for clinical trials, which Arius plans to initiate in 2008.

    Arius is advancing the formal preclinical toxicology program for its lead CD44 cancer stem cell program, an anticancer antibody targeting a novel epitope of CD44 found in breast, colon, and prostate cancers.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »